@article{2e92b8512651407e8c718c2f3d9bc551,
title = "A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach",
abstract = "NA",
keywords = "Phase I clinical trial, chronic lymphocytic leukaemia, elderly patients, milatuzumab, performance status",
author = "Michal Haran and Vita Mirkin and Nurith Harpaz and Olga Shevetz and Marina Shtreiter and Shulamit Greenberg and Orly Mordich and Orna Amram and Inbal Binsky-Ehrenreich and Ayelet Marom and Idit Shachar and Yair Herishanu and Rosa Ruchlemer and Alain Berrebi and Liora Valinsky and Mordechai Shtalrid and Lev Shvidel",
note = "Funding Information: Haran designed the research, performed the research, analysed the data and wrote the paper. Mirkin performed the research, analysed the data and wrote the paper. Braester performed the research, Harpaz performed the research, Shvetz performed the research and wrote the paper, Shtreiter designed and performed the research, Greenberg, Amram, Mordich, Binsky, Marom performed the research, Ruchlemer and Herishanu provided essential reagents and tools, Shachar performed the research and wrote the paper, Valinsky analysed the data, Shtalrid (deceased) designed and performed the research, Shvidel designed the research and wrote the paper. The authors would like to thank the Israeli CLL study group for participation and support, Dr. David Goldenberg and Imunomedics for kindly providing the study medication. This study was funded by a grant from the Israel Cancer Association.",
year = "2018",
month = jul,
doi = "10.1111/bjh.14726",
language = "الإنجليزيّة",
volume = "182",
pages = "125--128",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley and Sons Inc.",
number = "1",
}
